Gogineni Vijayakumar, General Director of Varthamana International Traders has arrived in the Republic of Ingushetia. The Chairman of the Government of the Republic of Ingushetia held a working meeting.
A Nuclear Medicine Center may be soon established in the Ural region as a result of efforts by the specialists of the Institute of Reactor Materials (an enterprise of Scientific Division of Rosatom State Corporation).
A pharmaceutical plant in Skidel (Belarus) will be launched in October, announced the press service of the Council of Republic following the meeting between curator of the Belarusian-Indian cooperation and Indian investors
Fermion Oy, a privately held Finnish manufacturer of active pharmaceutical ingredients (APIs), has reached a significant milestone in its investment project by entering the commissioning phase of its new plant in Hanko (Finland).
Moscow Endocrine Plant will acquire all sites of the former enterprise for destruction of chemical weapons in the Bryansk region in Q1 2019 aiming at establishing an affiliate for manufacturing active pharmaceutical substances.
An official ceremony marking the launch of construction was held at the site of future plant for active pharmaceutical substances and finished medicinal products of Pharmasyntez-Chemie in Usolye-Sibirskoye on June 15.
New drug manufacturing plant will be built in Atyrau (Kazakhstan). The project involves Meditsina JSC, NK SPK Atyrau JSC, and Sava Health Care, an Indian company. The construction is scheduled for completion in 2018.
WuXi Biologics announced that it is to invest $60 million and hire approximately 150 employees to establish a state-of-the-art biologics clinical and commercial manufacturing facility in Worcester, Massachusetts (USA).
Biosintez is one of the largest Russian pharma manufacturers. Its products range from substances to finished medicines, including tablets, ointments, suppositories, powders for injections, injection and infusion solutions.
The construction of a pharmaceutical plant to produce drugs for the treatment of oncological diseases will begin this year and the investment in the project at the first stage of its implementation will reach $10 million.
The Republic of Ingushetia intends to sign 9 agreements and contracts on cooperation with major corporations and a number of Russian entities during the 22nd St. Petersburg International Economic Forum (SPIEF).
WuXi Biologics, a leading global open-access biologics technology platform company, announced that it is to build an integrated biologics development, clinical and commercial manufacturing center in Northern China.